81 results
8-K
EX-99.1
MCRB
Seres Therapeutics Inc
5 Mar 24
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
7:05am
—related party.
Research and development expenses for the fourth quarter of 2023 were $26.8 million, compared with $46.2 million for the same period … in 2022. The research and development expenses were primarily related to Seres’ VOWST clinical development program and manufacturing costs, as well
8-K
EX-99.1
ido0d5
2 Nov 23
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
7:05am
8-K
EX-99.1
0zok5jjyg7826l2 rtak
8 Aug 23
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
7:05am
8-K
EX-99.1
ylbi2zwfjs36lhewe
9 May 23
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
8:16am
PRE 14A
42ixylkck9soqw
14 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.1
9bx4xze
2 Nov 22
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:10am
8-K
EX-99.1
yl8vb
3 Aug 22
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides
7:15am
424B5
hrs7y
30 Jun 22
Prospectus supplement for primary offering
7:59am